Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Aug;52(3):561-562.
doi: 10.1111/apt.15862.

Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail

Ashish Srinivasan  1   2   3 , Peter De Cruz  1   4 , Daniel R van Langenberg  1   3
Affiliations
Comment

Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail

Ashish Srinivasan et al. Aliment Pharmacol Ther. 2020 Aug.
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

REFERENCES

    1. Alric H, Amiot A, Kirchgesner J, et al. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor. Aliment Pharmacol Ther. 2020;51:948-957.
    1. Chapuis-Biron C, Bourrier A, Nachury M, et al. Vedolizumab for perianal Crohn’s disease: a multicentre cohort study in 151 patients. Aliment Pharmacol Ther. 2020;51:719-727.
    1. Biron C, Seksik P, Nachury M, et al. DOP74 efficacy of ustekinumab in perianal Crohn’s disease: the BioLAP multi-centre observational study. J Crohns Colitis. 2019;13;S074-S075.

LinkOut - more resources